Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Non-Current Debt (2016 - 2025)

Historic Non-Current Debt for Cumberland Pharmaceuticals (CPIX) over the last 16 years, with Q3 2025 value amounting to $5.2 million.

  • Cumberland Pharmaceuticals' Non-Current Debt fell 4812.53% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year decrease of 4812.53%. This contributed to the annual value of $10.2 million for FY2024, which is 2040.01% down from last year.
  • Per Cumberland Pharmaceuticals' latest filing, its Non-Current Debt stood at $5.2 million for Q3 2025, which was down 4812.53% from $5.2 million recorded in Q2 2025.
  • Cumberland Pharmaceuticals' 5-year Non-Current Debt high stood at $20.0 million for Q1 2022, and its period low was $5.2 million during Q1 2025.
  • Moreover, its 5-year median value for Non-Current Debt was $15.0 million (2021), whereas its average is $13.4 million.
  • Its Non-Current Debt has fluctuated over the past 5 years, first skyrocketed by 3571.43% in 2022, then tumbled by 6743.19% in 2025.
  • Quarter analysis of 5 years shows Cumberland Pharmaceuticals' Non-Current Debt stood at $15.0 million in 2021, then grew by 8.0% to $16.2 million in 2022, then dropped by 21.09% to $12.8 million in 2023, then decreased by 20.4% to $10.2 million in 2024, then crashed by 48.5% to $5.2 million in 2025.
  • Its last three reported values are $5.2 million in Q3 2025, $5.2 million for Q2 2025, and $5.2 million during Q1 2025.